Robert Z Orlowski, MD, PhD | Authors


Dr. Robert Z Orlowski on the Importance of the Phase III SWOG S0777 Trial

December 15, 2015

Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.